A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Multiple Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese or Overweight Type 2 Diabetic Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2009
At a glance
- Drugs Trodusquemine (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- 16 Apr 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 16 Apr 2009 Planned number of patients changed from 21 to 22 as reported by ClinicalTrials.gov.
- 16 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.